Focused On-demand Library for Tropomyosin alpha-3 chain

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P06753

UPID:

TPM3_HUMAN

Alternative names:

Gamma-tropomyosin; Tropomyosin-3; Tropomyosin-5

Alternative UPACC:

P06753; D3DV71; P12324; Q2QD06; Q5VU58; Q5VU63; Q5VU66; Q5VU71; Q5VU72; Q8TCG3; Q969Q2; Q9NQH8

Background:

The Tropomyosin alpha-3 chain, known alternatively as Gamma-tropomyosin, Tropomyosin-3, or Tropomyosin-5, plays a pivotal role in muscle and non-muscle cells. It binds to actin filaments, crucial for calcium-dependent regulation of vertebrate striated muscle contraction and stabilizing cytoskeleton actin filaments in non-muscle cells.

Therapeutic significance:

Linked to Congenital myopathy 4A and 4B, the Tropomyosin alpha-3 chain's mutations manifest in muscle weakness and respiratory insufficiency. Understanding its role could unveil new therapeutic strategies for these muscular disorders.